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Abstract
We report somatic mutations of RNF43 in over 18% of colorectal adenocarcinomas and 
endometrial carcinomas. RNF43 encodes an E3 ubiquitin ligase that negatively regulates Wnt 
signaling. Truncating mutations of RNF43 are more prevalent in microsatellite-unstable tumors 
and show mutual exclusivity with inactivating APC mutations in colorectal adenocarcinomas. 
These results indicate that RNF43 is one of the most commonly mutated genes in colorectal and 
endometrial cancers.
The E3 ubiquitin-protein ligase RNF43 negatively regulates the Wnt signaling pathway (1). 
Somatic mutations in RNF43 have been associated with heightened sensitivity to compounds 
that target the Wnt-specific acyltransferase porcupine (PORCN) in preclinical models (2). In 
parallel, clinical trials of small-molecule porcupine inhibitors (for example, LGK974) are 
ongoing in Wnt ligand-dependent malignancies (melanoma, pancreatic, breast, head and 
neck, and colorectal cancers). RNF43 is frequently mutated in pancreatic cystic neoplasms 
(3) and in <5% of pancreatic carcinomas with acinar differentiation (4); however, RNF43 
mutations have not been reported in melanoma (5), breast cancer (6), or head and neck 
malignancies (7). In colorectal cancer, Wnt signaling is more commonly dysregulated 
through loss-of-function APC mutations (8), whereas RNF43 has not been reported to be 
significantly mutated in prior sequencing studies (9, 10).
Unexpectedly, our whole-exome sequencing of colorectal cancers identified a large number 
of non-silent somatic mutations in RNF43. DNA isolated from a discovery set of 185 
formalin-fixed, paraffin-embedded colorectal tumor and matched normal samples collected 
from participants in 2 prospective cohort studies, the Nurses’ Health Study (NHS) and the 
Health Professionals Follow-up Study (HPFS) (11), showed RNF43 mutations in 35 (18.9%) 
cases (median allelic fraction of 0.23, range of 0.01–0.68) (Supplementary Table 1). 
Frameshift mutations encoding p.Gly659fs and p.Arg117fs constituting insertions or 
deletions of 1 bp in homopolymeric tracts (microsatellite instability (MSI) loci) of seven and 
six C:G pairs, respectively, accounted for 41.7% (p.Gly659fs) and 8.3% (p.Arg117fs) of the 
RNF43 mutations identified (Figure 1a). To exclude the possibility that these mutations 
represented technical artifacts, we validated 31 of the RNF43 mutations (97% of 32 
reactions that had leftover DNA available and achieved coverage of >50× in resequencing or 
successfully underwent Sanger sequencing) in the mutant tumors and their matched normal 
tissue (Supplementary Figure 1, Supplementary Table 1).
The unexpectedly high frequency of truncating RNF43 mutations in our colorectal tumor 
cohort contrasted with the paucity of RNF43 mutations reported by previous studies of a 
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comparable scale, including a TCGA (The Cancer Genome Atlas) study of 224 colorectal 
tumor-normal tissue pairs (9). We hypothesized that previous studies might have 
inadvertently filtered out many bona fide RNF43 frameshift events owing to their similarity 
to the polymerase slip errors that may arise during the massively parallel sequencing 
process. Therefore, we reanalyzed 222 TCGA colorectal tumor-normal exomes 
(representing all TCGA colorectal exomes available on our local servers in September 
2013). Of these, 49 cases (22%) were described in the published TCGA study (9). We 
discovered RNF43 mutations with high allelic fraction at a frequency of 17.6% (median 
allelic fraction of 0.38, range of 0.04–0.77; 48.0% encoding p.Gly659fs and 12% encoding 
p.Arg117fs mutations). We then orthogonally validated these mutations by examining 
matched RNA sequencing (RNA-seq) data, additionally confirming mRNA expression of 
the mutant RNF43 alleles (100% validation rate, 44 of 44 mutations in cases with at least 10-
fold coverage at the relevant base pair; Supplementary Table 2). These results confirmed 
that RNF43 is mutated at a high frequency in colorectal tumors (Figure 1b, Supplementary 
Table 2).
In light of this discovery, we reasoned that inactivating mutations in RNF43 might also have 
been overlooked in previous whole-exome sequencing studies of endometrial cancer, 
another Wnt-dependent tumor type in which MSI is common. A reanalysis of all 248 
endometrial tumor-normal exome pairs from the published TCGA study (12) identified the 
presence of non-silent RNF43 mutations in 18.1% of cases (median allelic fraction of 0.31, 
range of 0.04–0.87) with the p.Gly659fs variant accounting for 47.3% and the p.Arg117fs 
variant for 3.6% of the alterations (Figure 1c, Supplementary Table 3). Matched RNA-seq 
data orthogonally validated these events (91% validation rate, 20 of 22 mutations in cases 
with at least 10-fold coverage of the relevant base pair, Supplementary Table 3).
The high frequency of truncating mutations at this locus (together with a low frequency of 
synonymous mutations) strongly suggested that RNF43 mutations had undergone positive 
selection during colorectal and endometrial tumor evolution. To investigate this possibility, 
we analyzed RNF43 in each tumor exome cohort using InVEx, an algorithm we previously 
developed to infer the presence of positive selection in tumors with high background 
mutation rates (5). InVEx uses the exon/intron mutational distribution at a given locus to 
determine whether a gene has more mutations of predicted functional consequence than 
expected under a model of no selection. RNF43 emerged as significantly mutated in all three 
sample sets (NHS/HPFS colorectal cancer, P = 1.4 × 10−7; TCGA colorectal cancer, P = 4.1 
× 10−10; TCGA endometrial cancer, P = 2.0 × 10−7). Furthermore, given the empirical 
somatic indel rate at exonic homopolymeric tracts of seven C:G pairs in tumors with MSI, 
RNF43 indels causing p.Gly659fs occured significantly more often than expected by chance 
(P < 2.2 × 10−16, binomial test; 0.08–0.14% mutation frequency across all exonic 7-bp C:G 
tracts and 9.2–10.8% mutation frequency for the 7-bp C:G tract in RNF43 causing 
p.Gly659fs, calculated in tumors with MSI). RNF43 indels causing the p.Gly659fs alteration 
represented the most recurrent indels at exonic C:G homopolymeric tracts of any length in 
all three cohorts. Thus, RNF43 mutations apparently conferred a fitness advantage to the 
colorectal and endometrial cancer cells in which they occurred.
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As noted earlier, most RNF43 mutations (73–75% of all non-silent variants) were truncating 
events (defined as frameshift indels, nonsense mutations and splice-site mutations), 
consistent with the previous characterization of RNF43 as a tumor-suppressor gene (1). 
Additionally, 16 of 74 (21.6%) RNF43-mutant colorectal tumors (Supplementary Tables 1, 
2) and 8 of 45 (17.8%) RNF43-mutant endometrial tumors (Supplementary Table 3) 
harbored at least 2 non-silent RNF43 mutations, in line with the Knudson 2-hit hypothesis 
for tumor suppressor genes. We cannot exclude the possibility that the mutations affected 
the same allele in some two-hit cases, but this seems less likely given the overall loss-of-
function pattern.
Given that the RNF43 mutations were predominated by small insertions or deletions in 
homopolymeric tracts in tumor types with a high prevalence of MSI, we hypothesized that 
these mutations might be enriched in MSI tumors. Indeed, truncating mutations of RNF43 
were statistically linked to the microsatellite instability high (MSI-H) phenotype in both 
tumor types (P < 2.2 × 10−16 for colorectal cancer and P < 9.0 × 10−16 for endometrial 
cancer, Fisher’s exact test; Figure 2a, b). Overall, RNF43 was mutated in 79.7% of MSI-H 
colorectal tumors and 50.7% of MSI-H endometrial tumors (Supplementary Table 4). This 
association suggests that mismatch repair deficiency creates a permissive environment for 
the predominant RNF43 frameshift alterations affecting codons 659 and 117.
Inactivating RNF43 mutations should result in augmented Wnt signaling, owing to increased 
cell surface abundance of the Wnt receptor Frizzled (1, 2). We thus asked whether any of the 
significantly mutated Wnt pathway genes displayed a mutually exclusive pattern of mutation 
with RNF43 in colorectal or endometrial cancer. Indeed, truncating mutations in APC, the 
most frequently mutated gene in colorectal cancer, exhibited profound mutual exclusivity 
with truncating mutations in RNF43 (6 of 74 RNF43-mutant samples had co-occurring 
truncating mutations in RNF43 and APC, P < 2.2 × 10−16, Fisher’s exact test; 4 of 55 mutant 
samples had equivalent co-occurring truncating mutations when analysis was restricted to 
MSI-H tumors, P = 3.6 × 10−5; Figure 2a). Moreover, we detected RSPO3-PTPRK fusions 
(which activate Wnt signaling (10)) in two tumors, neither of which harbored RNF43 or 
APC mutations. The mutually exclusive relationship between mutations in RNF43 and APC 
provides additional genetic evidence in support of an activating role for truncating mutations 
of RNF43 in the Wnt pathway in colorectal cancer.
Our study demonstrates that RNF43 is a frequently mutated gene in colorectal and 
endometrial cancers, enriched in the setting of MSI. These findings further predict that 
stomach cancer, a third tumor type characterized by Wnt pathway dysregulation and 
frequent MSI (13), should also harbor frequent mutations in RNF43. Indeed, we found that 3 
of 37 (8.1%) published stomach cancer exomes (13, 14) had non-silent RNF43 mutations, 
including a mutation encoding p.Gly659fs. Moreover, while this manuscript was under 
review, two studies reported RNF43 mutations in gastric cancer (15, 16). These studies also 
demonstrated a higher percentage of RNF43 mutations in microsatellite-unstable samples in 
comparison to microsatellite-stable ones (54.6% versus 4.8% and 33% versus 3% in refs. 15 
and 16, respectively). The discovery of multiple tumor types with frequent mutations in 
RNF43 may have near-term clinical relevance in light of preclinical studies showing that 
RNF43 mutations render Wnt-driven cancer cells susceptible to pharmacologic porcupine 
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inhibition (2). More generally, these findings suggest that large-scale genomic analyses 
remain a fruitful means to discover biologically and clinically relevant changes in human 
cancer.
Methods
Tumor specimens
We collected 185 colorectal tumor-normal pairs from the participants of NHS and HPFS 
who were diagnosed with colorectal carcinomas (Supplementary Table 5). All of the 
colorectal tumor and adjacent normal colorectal tissue samples were collected according to 
Partners Human Research Committee institutional review board (IRB)-approved protocols, 
and informed consent was obtained from all subjects. Hematoxylin and eosin slides prepared 
from formalin-fixed, paraffin-embedded blocks were examined for cancer extent, tumor 
grade and other tumor characteristics through pathology review (S.O.). MSI status for each 
colorectal cancer sample was determined using standard protocols (11). We extracted 
genomic DNA from formalin-fixed, paraffin-embedded samples using the Qiagen QIAamp 
DNA FFPE Tissue Kit. DNA quality was evaluated by quantification using the Quant-iT 
Pico Green dsDNA Assay Kit (Invitrogen) according to the manufacturer’s protocol.
DNA sequencing
TCGA exome sequence data were downloaded from CGHub (see URLs). The generation of 
sequencing data from the NHS and HPFS cohorts was performed using a protocol for 
formalin-fixed, paraffin-embedded samples that has been detailed previously (17). Briefly, 
whole-exome capture libraries were constructed from tumor and normal DNA after sample 
shearing, end repair, phosphorylation and ligation to barcoded sequencing adaptors. DNA 
was then subjected to solution-phase hybrid capture with SureSelect v2 Exome bait (Agilent 
Technologies), and we performed multiplexing of the samples and sequencing on Illumina 
HiSeq 2000 instruments. Average mean target coverage was 96× (Supplementary Table 6). 
For validation, we used the Fluidigm Access Array microfluidic device. PCR products were 
barcoded, pooled and subjected to Illumina sequencing on a MiSeq instrument to a mean 
coverage of 11000×. For six samples, validation of the c.1976delC (p.Gly659fs) mutation 
was performed by amplifying and Sanger sequencing (Genewiz) a 211-bp product 
containing the change of interest (Supplementary Figure 1 and Supplementary Table 7).
Exome sequencing data analysis
Sequence analysis was performed as previously described (17, 18) to identify somatic 
single-nucleotide variants and short insertion or deletion events (Supplementary Tables 8–
10). Somatic mutations were called with the MuTect algorithm (18), and somatic indels 
were called with the Indelocator algorithm (see URLs). Manual review of all RNF43 indels 
in the NHS and HPFS cohorts was conducted using the Integrated Genomics Viewer (19), 
leading to deletions at base pair 56,435,160 being considered sequencing artifacts and 
excluded from further analysis. During manual review, it was discovered that several indels 
in RNF43 resulting in p.Gly659fs were discarded as ‘germline’ indels by Indelocator owing 
to the presence of a small number of reads supporting the variant in the normal exome. 
Indels likely to be somatic but originally filtered out as germline by Indelocator were 
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rescued across the exome if they passed the following conservative criteria: coverage of at 
least 50 reads in both tumor and normal samples, >20% of reads supporting the variant in 
tumor samples and <5% of reads supporting the variant in normal samples.
RSPO fusion determination
TCGA RNA-seq data corresponding to the 222 samples in the analyzed colorectal cancer 
exome TCGA set were downloaded from CGHub (219 of 222 samples had available RNA-
seq data). Gene fusions were called with TopHat-Fusion (20).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
RNF43 mutations in colorectal and endometrial cancers. (a–c) Distribution and type of 
RNF43 mutations in colorectal cancer, NHS and HPFS set (a); colorectal cancer, TCGA set 
(b); and endometrial cancer, TCGA set (c). The domains of RNF43 are depicted 
schematically at the bottom.
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Figure 2. 
Association of RNF43 mutations with MSI status and APC mutations. (a) Matrix displaying 
MSI status, APC truncating events and RNF43 truncating events for each of 407 colorectal 
tumor samples (NHS set and HPFS set and TCGA set). Each vertical line represents one 
colorectal cancer. Top, MSI status. MSI-H, microsatellite instability high; MSI-L, 
microsatellite instability low; MSI-NA, MSI status not available; MSS, microsatellite stable. 
Middle, a filled box shows that an APC truncating mutation is present in that tumor. Bottom, 
a filled box shows that an RNF43 truncating mutation is present in that tumor. (b) Matrix 
displaying MSI status and RNF43 truncation status for each of 248 endometrial tumor 
samples (TCGA set). Each vertical line represents one endometrial cancer. Top, MSI status. 
Bottom, a filled box shows that an RNF43 truncating mutation is present in that tumor. 
Mutations in APC and RNF43 are colored by type. In cases where multiple mutations were 
present in the same cancer sample, the presence of a frameshift mutation took priority in 
determining the displayed color, followed by the presence of a nonsense mutation.
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